SPINAL MUSCULAR (SMN1/SMN2) DETECTION DUPLICATION ANALYSIS

Spinal Muscular (SMN1/SMN2) Detection Duplication Analysis is an advanced molecular genetic test used to evaluate copy number variations, deletions, and duplications involving the SMN1 and SMN2 genes. These genes play a critical role in the production of Survival Motor Neuron (SMN) protein, which is essential for the health and function of motor neurons responsible for muscle movement and strength.

This test is primarily used in the diagnosis and carrier screening of Spinal Muscular Atrophy (SMA), a hereditary neuromuscular disorder characterized by progressive muscle weakness and motor neuron degeneration. Analysis of SMN1 and SMN2 gene copy numbers provides valuable diagnostic, prognostic, and genetic counseling information for affected individuals and families.

Benefits of the Test

• Detects SMN1 gene deletions and duplications associated with SMA.
• Determines SMN2 gene copy number status.
• Supports early diagnosis of Spinal Muscular Atrophy.
• Assists in carrier detection and family screening.
• Provides important prognostic information.
• Supports genetic counseling and reproductive planning.
• Facilitates treatment planning and disease management.
• Offers highly accurate molecular genetic assessment.

Why Doctors Recommend This Test

Doctors recommend SMN1/SMN2 Detection Duplication Analysis for patients with symptoms suggestive of Spinal Muscular Atrophy, infants with hypotonia or muscle weakness, individuals with a family history of SMA, couples planning pregnancy, and those requiring carrier screening. The test helps confirm diagnosis and assess genetic risk.

Preparation Before Test

• No fasting is generally required.
• A blood sample is collected for genetic analysis.
• Provide previous genetic testing reports if available.
• Share family history of neuromuscular disorders.
• Inform your doctor about relevant medical conditions.
• Follow all sample collection instructions provided by the laboratory.

Normal Reporting Time

Most SMN1/SMN2 Detection Duplication Analysis reports at Focus Diagnostics are initiated within 2–3 hours of sample receipt for accessioning, DNA extraction, and molecular workflow preparation. Final copy number analysis, quality verification, interpretation, and report generation are generally completed within several working days depending on laboratory procedures and quality assurance requirements.

Who Should Take This Test?

This test may be recommended for:

• Patients with suspected Spinal Muscular Atrophy.
• Infants with muscle weakness or developmental delays.
• Individuals with unexplained neuromuscular symptoms.
• People with a family history of SMA.
• Couples planning pregnancy.
• Individuals seeking carrier screening.
• Patients requiring genetic counseling.
• Families at risk for inherited neuromuscular disorders.

Detailed Information

Spinal Muscular Atrophy is one of the most common inherited neuromuscular disorders and is caused primarily by mutations or deletions in the SMN1 gene. The condition affects motor neurons located in the spinal cord, leading to progressive muscle weakness, impaired movement, difficulties with mobility, and in severe cases, respiratory complications.

The SMN1 gene produces the majority of functional Survival Motor Neuron protein. When both copies of SMN1 are absent or defective, insufficient protein production results in degeneration of motor neurons. The severity of the disease is often influenced by the number of copies of the SMN2 gene, which can partially compensate for the loss of SMN1 function.

SMN2 copy number analysis provides important prognostic information because individuals with higher SMN2 copy numbers may experience milder disease manifestations compared with those having fewer copies. Therefore, assessment of both SMN1 and SMN2 genes is considered an essential component of comprehensive SMA evaluation.

The test utilizes advanced molecular diagnostic technologies to accurately determine gene copy numbers and detect clinically significant deletions or duplications. Results are interpreted alongside clinical findings, neurological assessments, and family history information.

Early diagnosis of SMA is particularly important because newer targeted therapies and disease-modifying treatments are most effective when initiated promptly. Genetic confirmation enables timely intervention, appropriate clinical management, and informed healthcare decisions.

Carrier screening is also valuable for couples planning a family, as SMA follows an autosomal recessive inheritance pattern. Identifying carrier status can help assess reproductive risks and support informed family planning.

At Focus Diagnostics, SMN1/SMN2 Detection Duplication Analysis is performed using advanced molecular genetics platforms, validated copy number analysis methodologies, and stringent quality assurance standards to provide accurate, reliable, and clinically meaningful genetic testing results.